Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome

Inclusion criteria:. * Male or female patients ≥ 18 years of age. * Post-gastric or esophageal bypass surgery, matching one of the criteria below: * Bariatric surgery: more than 6 months before signing the informed consent * Esophageal cancer surgery: were disease free at study entry * Gastric cancer surgery: were at stage 0 or I and were disease free at study entry * Patient with a documented diagnosis of Dumping Syndrome defined as having: * History of/or active symptoms associated with dumping syndrome (e.g. post-prandial tachycardia, bloating, diarrhea) and * Documented history of hypoglycemia based on either: * glucose \<50 mg/dL or 2.8 mmol/L on a sporadic or scheduled blood analysis -or * glucose value \<60 mg/dL or ≤ 3.3 mmol/L at 90, 120, 150 or 180 min during an OGTT * Patients had at least one glucose level \<60 mg/dL (or ≤ 3.3 mmol/L) at 90, 120, 150 or 180 min during the 3-hour OGTT at screening. * Patients with esophageal cancer with a negative computed tomography (CT) or Magnetic resonance imaging (MRI) scan (neck, thoracic, and upper abdominal) and albumin ≥ 3.5 g/dl at baseline. * Patients with gastric cancer with a negative CT or MRI scan (total abdomen). * Karnofsky Performance Status ≥ 60 (i.e. required occasional assistance, but was able to care for most of their personal needs) * Patients who received other therapies for dumping syndrome (such as acarbose, gama guar, pectin) must have stopped all treatments and had a wash out period prior to signing …